Moving forward with mRNA medicines

September 5, 2018, American Chemical Society

In cells, ribosomes translate messenger RNA (mRNA) into proteins. And in the nascent field of mRNA therapeutics, researchers and investors are hoping to translate mRNA drugs from the lab to the medicine cabinet. Until now, the mRNA firm Moderna Therapeutics has been secretive about its technology, but now the company is opening up about its progress and challenges, reports an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.

Over the past five years, Moderna has spent an impressive $450 million on research into mRNA medicines and plans to spend another $500 million over the next five years, writes Assistant Editor Ryan Cross. Moderna and several other well-funded biotech firms are based on a seemingly simple principle: Introduce specially designed mRNA to certain of the body, and ribosomes will become miniature drug factories that churn out therapeutic proteins to treat almost any disease. However, the field has faced many hurdles, such as avoiding immune reactions, targeting specific cells, shuttling the mRNA safely inside and making enough protein to have an effect.

Moderna and other firms are addressing these challenges by optimizing the mRNA sequences and developing drug delivery mechanisms. For example, Moderna scientists have made lipid nanoparticles that deliver a special sequence of mRNA that causes cancer cells, but not normal cells, to self-destruct. Despite the promise of mRNA medicines, skeptics are quick to point out that Moderna has only published human data from one study, an early-stage trial on an mRNA flu vaccine. Companies must still prove that mRNA medicines work in humans without side effects or complications, they say.

Explore further: Methyl marks on RNA discovered to be key to brain cell connections

More information: "Can mRNA disrupt the drug industry?", cen.acs.org/business/start-ups … drug-industry/96/i35

Related Stories

Mixed mRNA tails act like a shield to delay its shortening

July 20, 2018

Cells curb the amount of specific proteins at any desired time via the control of mRNA degradation. As mRNA nucleotides tail plays a role in this process, biologists at the Center for RNA Research, within the Institute for ...

Recommended for you

New battery gobbles up carbon dioxide

September 21, 2018

A new type of battery developed by researchers at MIT could be made partly from carbon dioxide captured from power plants. Rather than attempting to convert carbon dioxide to specialized chemicals using metal catalysts, which ...

Scientists solve the golden puzzle of calaverite

September 21, 2018

Scientists from Russia and Germany have shed light on the crystalline structure of calaverite, foretelling the existence of a new gold compound previously unknown to chemists. The results of their study were published in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.